Safety, Tolerability, and Pharmacokinetics of Single Rising Intravenous Doses of BI 765845 in Healthy Male Japanese Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
Latest Information Update: 02 Jan 2024
At a glance
- Drugs BI-765845 (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 28 Dec 2023 Status changed from active, no longer recruiting to completed.
- 23 Nov 2023 New trial record